华海药业：关于子公司通过美国FDA现场检查的公告

Core Viewpoint - Huahai Pharmaceutical's subsidiary, Zhejiang Huahai Pharmaceutical Technology Co., has successfully passed an FDA inspection, confirming compliance with CGMP standards for its production facility [2]. Group 1 - The FDA conducted an on-site inspection from August 18 to August 22, 2025, focusing on the overall quality management system and oral solid dosage products of Huahai Technology [2]. - The inspection report indicates that Huahai Technology's production base meets the requirements of current Good Manufacturing Practice (CGMP) for pharmaceuticals [2].